ABPI Says Patients Should Have A Say In Health Issues

18 December 1995

Patients must have an equal say in the debate on any rationing of health resources, according to a report by the Association of the British Pharmaceutical Industry. The report, entitled Putting Patients First, examines the progress made in giving patients an effective voice in the treatment of their disease.

"Sensible solutions will not be reached on the debate now taking place on the rationing of resources if the major stakeholders, the users, are not able to have an equal say in the process," says Christina Funnell, chairperson of the Long-Term Medical Conditions Alliance, and who is also chief executive of the UK's National Eczema Society.

Ms Funnell would like to see structures put in place that will give status and authority to patients when it comes to the decision-making process in the health service. In order to achieve this Ms Funnell envisages: - A patients' advisory committee serviced by the civil service, and with real powers to work with the Secretary of State for Health in developing and influencing policy; - patient representatives, advocates and users appointed to all decision-making committees with the National Health Service and the Department of Health; and - well- resourced, independent national bodies which are able to make informed contributions, both nationally and locally, on behalf of patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight